Get started
Work

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

Year: 2020
Type: article
Study design: Observational Study
DOI: 10.1016/j.annonc.2020.04.471
Authors: C.N. Owen, A.N. Shoushtari, D. Chauhan, D.J. Palmieri, B. Lee, M.W. Rohaan, J. Mangana, V. Atkinson, F. Zaman, A. Young, C. Hoeller, P. Hersey, R. Dummer, M.A. Khattak, M. Millward, S.P. Patel, A. Haydon, D.B. Johnson, S. Lo, C.U. Blank, S. Sandhu, M.S. Carlino, J.M.G. Larkin, A.M. Menzies, G.V. Long
Institutions: The University of Sydney, Melanoma Institute Australia, Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, Westmead Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, The Netherlands Cancer Institute, University Hospital Zurich, The University of Queensland, Greenslopes Private Hospital, Princess Alexandra Hospital, The Alfred Hospital, Vanderbilt University Medical Center, Medical University of Vienna, The University of Western Australia, Fiona Stanley Hospital, The University of Texas MD Anderson Cancer Center, Royal North Shore Hospital
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Endocyte, Les Laboratories Pierre Fabre, Incyte, Cancer Institute NSW, Eisai, Ipsen, EUSA Pharma, National Institutes of Health, Genentech, Pharmacyclics, National Heart, Lung, and Blood Institute, National Cancer Institute
OpenAlex ID: W3021358555
FWCI: 5.325
Cites: 22
Cited by: 111
Related to: 10